Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Shots:
- The P-III NALA Trial involves assessing of Neratinib + capecitabine vs Tykerb (lapatinib) + capecitabine in 621 patients in ratio (1:1) with HER2-Positive Metastatic Breast Cancer
- The P-III NALA Trial demonstrated improvement in PFS by 1% and OS by 4% with safety profile consistent with previous trials
- Neratinib is an irreversible tyrosine kinase inhibitor- or TKI used for blocking signal transduction through EGFRs- HER1- HER2 and HER4- approved by the US FDA for early stage HER2-overexpressed/amplified breast cancer in adults
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
